# Alvin Luk

> Alvin Luk is a biotech executive, neuroscientist and entrepreneur with more than three decades in global drug development. He is President & Chief Medical Officer (Group) and U.S. CEO of HanchorBio, a clinical-stage immunology and immuno-oncology company building Fc-based designer biologics, and co-founder and CEO of CRISPR gene-editing company HuidaGene Therapeutics. Across his career he has contributed to roughly two dozen approved products and more than 250 global regulatory submissions, including LUXTURNA, the first FDA-approved gene therapy. A 2025 TIME100 Health honoree, he wants to turn HanchorBio into the 'Genentech of Asia.'

- **Role:** President & Chief Medical Officer (Group) and CEO (U.S.) at HanchorBio Inc.
- **Organizations:** HanchorBio Inc., HuidaGene Therapeutics, Neurophth Therapeutics, Shanghai Henlius Biotech, Spark Therapeutics, Biogen / Bioverativ, Bayer, Zhongmou Therapeutics
- **Nationality:** United States
- **Education:** Ph.D., M.B.A., C.C.R.A. (Certified Clinical Research Associate)
- **Known for:** Contributed to roughly 22 approved medicines across his career, More than 250 cumulative IND, BLA and MAA regulatory submissions across the Americas, Europe, Asia and Australia, Helped drive clinical development of LUXTURNA, the first FDA-approved gene therapy

## Career timeline

- **1990s-2000s** — Held roles across Tularik (acquired by Amgen), Avigen (acquired by Sanofi Genzyme) and Bayer Pharmaceuticals
- **2010s** — Senior roles at Biogen / Bioverativ (Hemophilia Division, acquired by Sanofi) and Spark Therapeutics (acquired by Roche), contributing to gene therapy and hemophilia programs
- **2010s** — Chief Medical Officer and SVP of Global Clinical and Medical Affairs at Shanghai Henlius Biotech
- **2021** — As CEO of Neurophth Therapeutics, expanded the pipeline from 1 to 10 AAV gene therapy programs and raised over $120 million
- **2022** — Joined the board of directors of HanchorBio
- **2023** — Appointed Co-Founder, Board Member and CEO of HuidaGene Therapeutics (May)
- **2024** — HuidaGene's HG202 cleared by FDA for a Phase 1 trial in neovascular age-related macular degeneration; first patients dosed in Duchenne and MECP2 duplication trials
- **2025** — Named to the TIME100 Health list; delivered one of three Presidential Symposium talks at ASGCT 2025; appointed Group President and Chief Medical Officer at HanchorBio (November)

## Achievements

- Contributed to roughly 22 approved medicines across his career
- More than 250 cumulative IND, BLA and MAA regulatory submissions across the Americas, Europe, Asia and Australia
- Helped drive clinical development of LUXTURNA, the first FDA-approved gene therapy
- Worked on BEQVEZ hemophilia gene therapy in partnership with Pfizer
- Named to TIME100 Health 2025 for contributions to rare disease innovation
- Secured 11 orphan drug or rare pediatric disease designations in 15 months at HuidaGene
- Grew Neurophth's pipeline from 1 to 10 AAV gene therapy programs and raised over $120M

## Latest updates

- **2025-11** — Appointed Group President and Chief Medical Officer at HanchorBio to lead its next stage of growth.
- **2025-05** — Named to the TIME100 Health list and delivered a Presidential Symposium talk at ASGCT 2025 on CRISPR editing for Duchenne muscular dystrophy.
- **2026-02** — HanchorBio accelerated its global clinical footprint with multiple oral and poster presentations and reported strong HCB101 combination data in gastric cancer.

## Links

- Website: https://hanchorbio.com
- LinkedIn: https://www.linkedin.com/in/alvin-luk

---

Profile page: https://yespress.io/alvin-luk
Published by YesPress — https://yespress.io
Last updated: 2026-06-14